Integra LifeSciences Holdings
IARTIntegra LifeSciences Holdings is a global medical device company specializing in surgical instruments, neuro and spinal devices, and wound care products. Founded in 1989, it focuses on developing innovative solutions for healthcare providers to improve patient outcomes across neurosurgery, orthopedics, and general surgery.
Company News
Integra LifeSciences reported Q3 2025 revenues of $402.1 million, a 5.6% increase from the previous year. The company saw healthy demand across its portfolio, with strong profitability driven by disciplined cost management and operational efficiencies.
The US breast reconstruction market is projected to grow from $1.02 billion in 2024 to $1.74 billion by 2033, driven by rising breast cancer incidences, improved surgical techniques, and increased insurance coverage.
The global craniomaxillofacial devices market is projected to grow from $1.8 billion in 2024 to $3.9 billion by 2034, driven by increased facial injuries, technological advancements, and minimally invasive surgical techniques.
Integra LifeSciences Holdings Corporation reported weaker-than-expected financial results for the first quarter of 2025, leading to a significant drop in its stock price. The Pomerantz Law Firm is investigating potential securities fraud or other unlawful business practices by the company and its officers.
Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. (CAPR) after the company announced that the FDA will hold an advisory committee meeting for its Biologics License Application, causing the stock price to drop.
